#USA #ALS Research #Clearwater #ProJenX #Prosetin

ProJenX to Present Updates on Prosetin Development Program at 2026 NEALS Annual Meeting

ProJenX, a clinical-stage biotechnology firm focused on developing novel therapies for brain diseases, is making waves in the scientific community. At the 2026 Network for Excellence in ALS (NEALS) Annual Meeting held from October 27-30 in Clearwater, Florida, the company will provide important updates on its promising prosetin development program. This program focuses on treating amyotrophic lateral sclerosis (ALS) and other significant neurological conditions.

Prosetin is recognized as a selective MAP4K inhibitor that penetrates the central nervous system (CNS). It is currently being evaluated in a Phase 1b study named PRO-101 involving ALS patients. This particular inhibitor has garnered attention for its potential effectiveness in addressing neurodegenerative diseases by targeting the mechanisms underpinning cellular dysfunction.

During the NEALS meeting, ProJenX will present long-term clinical data gathered from the PRO-101 study, laying out its findings on the safety and tolerability of prosetin. Additionally, the company will introduce exciting new preclinical results that highlight prosetin's ability to rectify TDP-43-related malfunctions in neuronal cells derived from human stem cells.

CEO Stan Abel emphasized the significance of their findings, stating, "The body of data we've generated strengthens the case for MAP4K as an important target in ALS and related neurodegenerative diseases. In PRO-101, we achieved therapeutic exposure levels that aligned with our objectives, and we maintained a favorable safety profile over long-term treatment. These results propose that inhibiting MAP4K within the CNS is a clinically viable approach. We extend our gratitude to the participants, investigators, and community advisors who have been integral to our progress."

Presentation Details

• - Date: Wednesday, October 28
• - Type: Poster Presentation
• - Time: 4:50 PM ET
• - Poster Number: 56
• - Topic: Preclinical characterization of prosetin, a novel, CNS-penetrant MAP4K inhibitor for ALS treatment

• - Date: Thursday, October 29
• - Type: Oral Presentation
• - Time: 9:50 AM ET
• - Session: Collaborative Ecosystem for Clinical Trial Innovation
• - Topic: Early incorporation of lived experience in the prosetin development
• - Type: Poster Presentation
• - Time: 4:50 PM ET
• - Poster Number: 207
• - Topic: Results from PRO-101, a Phase 1b clinical study evaluating safety, tolerability, PK, and PD of prosetin in ALS patients

About Prosetin

Prosetin stands as a promising oral MAP4K inhibitor under rigorous evaluation for ALS treatment. Initially spotlighted for its regulation of motor neuron loss due to proteotoxic stress, groundbreaking research hails from a collaborative discovery platform established by ProJenX's founders at Columbia University. Latest preclinical findings indicate that MAP4K inhibition could provide broad neuroprotective effects across various models of ALS, including significant reparative effects on TDP-43 pathology.

Prosetin remains an investigational new drug that has not yet received FDA approval. The continuous advancements and optimism surrounding prosetin echo the ongoing commitment of ProJenX to push the frontiers of neurological research. As they prepare for the NEALS conference, all eyes will be on the new data that could reshape future treatment paradigms for ALS patients.

About ProJenX

Founded through a significant collaboration between Project ALS and leading Columbia University researchers, ProJenX is a clinical-stage biotechnology company dedicated to launching innovative, targeted therapies for severe brain diseases like ALS. Their patient-centric cell-based drug discovery platform seeks to accelerate advancements in treatment development for neurodegenerative disorders. For further details, visit projenx.com.